L002 NEW
| Price | $34 | $34 | $54 | $54 | $81 | $81 |
| Package | 2mg | 2mg | 5mg | 5mg | 10mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-04-22 |
Product Details
| Product Name: L002 | CAS No.: 321695-57-2 |
| Purity: 98.59% | Supply Ability: 10g |
| Release date: 2026/04/22 |
Product Introduction
Bioactivity
| Name | L002 |
| Description | L002, a potent, cell-permeable, reversible, and specific acetyltransferase p300 (KAT3B) inhibitor with an IC50 of 1.98 μM, directly binds the acetyl-CoA pocket and competitively inhibits the FATp300 catalytic domain. By blocking histone acetylation, p53 acetylation, and STAT3 activation, L002 shows potential in the treatment of hypertension‐induced cardiac hypertrophy and fibrogenesis. |
| In vitro | L002 also has weak inhibitory effects against PCAF and GCN5 (IC50s =35 and 34 μM, respectively) and is specific for p300 over a panel of deacetylases, additional acetyltransferases, and methyltransferases. |
| In vivo | L002 reverses hypertension‐induced cardiac hypertrophy and fibrosis by treatment of mice after inducing hypertension for two weeks significantly.It also reduces the levels of perivascular and interstitial collagen in the myocardium compared to non-treated hypertensive mice. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.22 mM), Sonication is recommended. DMSO : 60 mg/mL (186.71 mM), Sonication is recommended. |
| Keywords | STAT | PCAF | p300 | L-002 | L002 | L 002 | KAT3B | Inhibitor | inhibit | HistoneAcetyltransferase | Histone Acetyltransferase | histone | HATs | HAT | GCN5 | fibrosis | cardiac | acetylation |
| Inhibitors Related | Flubendazole | HODHBt | 3-methyl-1,2,3,4-tetrahydroquinazolin-2-one | Acetaminophen | Nifuroxazide | Balsalazide disodium dihydrate | Manganese chloride (tetrahydrate) | Curcumin | Niclosamide | N4-Acetylcytidine | Naphthol AS-E | Niclosamide olamine |
| Related Compound Libraries | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Hematonosis Compound Library | JAK-STAT Compound Library | Inhibitor Library | Anti-Fibrosis Compound Library | Stem Cell Differentiation Compound Library | Anti-Prostate Cancer Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Transcription Factor-Targeted Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $34.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-11 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY